Award

Supply and Installation of PhysioMimix OOC Multi-OrganFull System

THE UNIVERSITY OF BIRMINGHAM

UK5: Transparency notice - Procurement Act 2023 - view information about notice types
Notice identifier: 2025/S 000-034566
Procurement identifier (OCID): ocds-h6vhtk-05522d
Published 24 June 2025, 9:10am

Scope

Reference

SC13833/25

Description

The PhysioMimix® Multi-Tissue System is particularly well suited for use in a core facility (Birmingham Tissue Analytics), where flexibility and broad applicability are key. Its modular design allows different organ models to be easily configured and reconfigured to suit a range of project needs-from single-organ toxicity studies to multi-organ interaction and disease modelling. With standardized protocols and user-friendly operation, it supports consistent, high-quality data generation across diverse applications, making it an efficient and adaptable platform for multiple research groups and project types.

Contract 1

Supplier

- CN Bio Innovations Limited

Contract value

- £298,045 excluding VAT
- £298,045 including VAT

Above the relevant threshold

Earliest date the contract will be signed

24 June 2025

Contract dates (estimated)

- 2 July 2025 to 28 May 2026
- 10 months, 27 days

Main procurement category

Works

CPV classifications

- 45214630 - Scientific installations

Contract locations

- UK - United Kingdom

Participation

Particular suitability

Small and medium-sized enterprises (SME)

Other information

Conflicts assessment prepared/revised

Yes

Procedure

Procedure type

Direct award

Direct award justification

Extreme and unavoidable urgency

The PhysioMimix® Multi-Tissue System offers a highly advanced, solution for modelling systemic human biology in vitro. By enabling the dynamic co-culture of multiple organ models-such as liver, gut, and lung-within a single, perfused microphysiological system, it provides a unique opportunity to assess inter-organ interactions, drug metabolism, distribution, and toxicity in a more integrated and human-relevant context. Product features include an open-well consumable plate design, media is pneumatically pumped recirculated through microfluidics within these plates to perfuse tissue cultures. Modular PhysioMimix® hardware consists of a Controller, Docking Station(s), and MPS driver(s), and consumable plates controlled via proprietary software. This is underpinned by patents exclusively licensed from MIT to CN Bio.

This system is particularly valuable for studying drug pharmacokinetics and pharmacodynamics (PK/PD) across tissues, evaluating how metabolites formed in one organ (e.g., liver) influence the function or toxicity of others. Such capability is crucial for understanding off-target effects, bioactivation pathways, and multi-organ toxicity that are often missed in single-organ or animal models.

Supplier

CN Bio Innovations Limited

- Companies House: 06517359

332 Cambridge Science Park

Cambridge

CB4 0WN

United Kingdom

Email: adrian.rea@cn-bio.com

Region: UKH12 - Cambridgeshire CC

Small or medium-sized enterprise (SME): Yes

Voluntary, community or social enterprise (VCSE): No

Contract 1

Contracting authority

THE UNIVERSITY OF BIRMINGHAM

- Companies House: RC000645
- Public Procurement Organisation Number: PHCQ-3464-LVTM

Edgbaston

Birmingham

B15 2TT

United Kingdom

Email: procurement@bham.ac.uk

Website: http://www.birmingham.ac.uk

Region: UKG31 - Birmingham

Organisation type: Public authority - sub-central government